10
total announcements
531752.BO · 15 min delayed
Biogen Pharmachem Industries Ltd
Biogen Pharmachem Industries Ltd submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026, confirming the dematerialization of securities and cancellation of physical certificates.
Biogen Pharmachem Industries Ltd
Biogen Pharmachem Industries Ltd has announced the voting results of its 31st Annual General Meeting, where all three resolutions were passed with significant majority. The resolutions include the adoption of audited financial statements, re-appointment of a director, and appointment of a new statutory auditor.
Biogen Pharmachem Industries Ltd
Biogen Pharmachem Industries Ltd has informed about the outcome of its 31st Annual General Meeting (AGM) held on September 29, 2026, where the shareholders passed the ordinary resolutions for adoption of audited financial statements, re-appointment of a director, and appointment of statutory auditors.
Biogen Pharmachem Industries Ltd
Biogen Pharmachem Industries Ltd has submitted its Annual Report for the financial year 2025-26, along with the Notice of Annual General Meeting to be held on September 29, 2026. The report includes audited financial statements, management discussion and analysis, corporate governance report, and auditor's report.
Biogen Pharmachem Industries Ltd
Biogen Pharmachem Industries Ltd has announced the book closure for its Annual General Meeting (AGM) from September 22 to September 29, 2026, and e-voting will take place from September 26 to September 28, 2026.
Biogen Pharmachem Industries Ltd
Biogen Pharmachem Industries Ltd has submitted a notice of its 31st Annual General Meeting (AGM) to be held on September 29, 2026, through video conferencing. The AGM will consider the audited financial statements for the year ended March 31, 2026, and other business.
Biogen Pharmachem Industries Ltd
Biogen Pharmachem Industries Ltd has informed that it does not have any unused funds from past public issues or placements, as per SEBI's Regulation 32(1) of the Listing Obligation and Disclosure Requirements.
Biogen Pharmachem Industries Ltd
Biogen Pharmachem Industries Ltd announced its unaudited standalone financial results for the quarter ended June 30, 2026, under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company reported a net profit of Rs. 22.14 lakhs, with a basic EPS of Rs. 0.00 and a diluted EPS of Rs. 0.00. The results were reviewed by the Audit Committee and approved by the Board of Directors.
Biogen Pharmachem Industries Ltd
Biogen Pharmachem Industries Ltd has announced its unaudited standalone financial results for the quarter ended June 30, 2026, with a net profit of Rs. 22.14 lakhs and a revenue from operations of Rs. 44.34 lakhs.
Biogen Pharmachem Industries Ltd
Biogen Pharmachem Industries Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 05/08/2026 to consider and approve the Un-Audited Financial Results for the first quarter ended on 30th June 2026.